Background: Estimation of the number of people in need of antiretroviral therapy (ART) in resource-limited settings requires information on the time from seroconversion to ART eligibility and from ART eligibility to death.
Objectives: To estimate duration from seroconversion to different ART eligibility criteria and from ART eligibility to death in HIV-infected adults in low-income and middle-income countries.
Methods: Participants with documented seroconversion from five cohorts (two cohorts from Uganda, two from Thailand and one from Côte d’Ivoire) were analysed. We used Weibull survival models and Bayesian simulation methods to model true (unobserved) first time of treatment eligibility. We set a consistency constraint so that the mean duration from seroconversion to death was equal to the mean from seroconversion to ART eligibility plus the mean from eligibility to death.
Results: We analysed data from 2072 participants, 16 157 person-years of follow-up and 794 deaths. For the criterion CD4 T-lymphocyte count <200 cells ×106/l, the median duration from seroconversion to ART eligibility was 6.1 years (95% credibility interval 3.3–10.4) for all studies and 7.6 years (95% credibility interval 3.4–15.2) for all but the Thai cohorts. Corresponding estimates for the time from CD4 T-lymphocyte count <200 cells ×106/l to death were 2.1 years (0.7–4.8) and 2.7 years (0.8–8.4). When including all cohorts, the mean time from serconversion to CD4 T-lymphocyte count <200 cells ×106/l and from CD4 T-lymphocyte count <200 cells ×106/l to death represented 66% (38–87%) and 34% (13–62%), respectively of the total survival time.
Conclusions: The duration of different ART eligibility criteria to death was longer than the estimates used in previous calculations of the number of people needing ART. However, uncertainty in estimates was considerable and heterogeneity across cohorts important.
Statistics from Altmetric.com
Competing interests: None.
The eART-linc collaboration writing group: Simon Wandel,1 Matthias Egger,1,2 Ram Rangsin,3 Kenrad E Nelson,4 Caroline Costello,5 Charlotte Lewden,6,7 Tom Lutalo,8 Anthony Ndyanabo,8 Jim Todd,9 Lieve Van der Paal,9 Albert Minga,10 Marcel Zwahlen1
1Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland; 2Department of Social Medicine, University of Bristol, UK; 3Department of Military and Community Medicine, Phramongkutklao College of Medicine, Thailand; 4Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; 5Department of Epidemiology, University of California, Los Angeles, CA, USA; 6INSERM, U593, Bordeaux, France; 7Institut de Santé Publique, d?Epidémiologie et de Developpement (ISPED), Université Victor Segalen, Bordeaux, France; 8Rakai Health Sciences Program, Uganda Virus Research Institute, Entebbe, Uganda; 9MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 10Programme PAC-CI, CNTS, Abidjan, Côte d'Ivoire.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.